SAN CARLOS, Calif., May 17, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the "Company"), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte ("TIL") therapies for patients with cancer, today announced that on May 16, 2024 (the "Date of Grant"), the Company approved the grant of inducement stock options covering an aggregate of 153,930 shares of Iovance's common stock to thirty new, non-executive emplo ...

Investors are misunderstanding when the biopharma company's flagship drug will begin generating meaningful reportable revenue.Iovance Biotherapeutics (IOVA -19.07%) shares are down to the tune of 18% today following Thursday evening's release of its first-quarter numbers. The sell-off clearly suggests investors didn't like everything they heard. The knee-jerk response to the news, however, looks past a critical detail regarding the report.An irrelevant quarterly reportIovance Biotherapeutics did $715,000 wo ...

Iovance Biotherapeutics, Inc. (IOVA) incurred a loss of 42 cents per share in first-quarter 2024, narrower than the Zacks Consensus Estimate of a loss of 45 cents. In the year-ago quarter, the company reported a loss of 50 cents.During the quarter, the company generated total revenues of $0.7 million — entirely from product sales of its recently-acquired interleukin-2 (IL-2) product Proleukin (aldesleukin). The reported sales missed the Zacks Consensus Estimate of $2.9 million. In the year-ago quarter, Iova ...

For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-36860 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 IOVANCE BIOTHERAPEUTICS, INC. (Exact name of issuer as specified in its charter) (State or other jurisdiction of (I. ...

Exhibit 99.1 Iovance Biotherapeutics Reports First Quarter 2024 Financial Results and Corporate Updates Strong Momentum for Amtagvi™ (Lifileucel) U.S. Launch Following U.S. Food and Drug Administration (FDA) Approval 100+ Amtagvi Patients Enrolled Across More Than 40 Current Authorized Treatment Centers (ATCs), with ~50 Total ATCs On Track by End of May and 70+ Total ATCs by Year-End 2024 Frederick Vogt, Ph.D., J.D., Interim President and Chief Executive Officer of Iovance, stated, "The first quarter of 202 ...

Iovance Biotherapeutics (IOVA) is scheduled to report first-quarter 2024 results on May 9, after market close. In the last reported quarter, the company’s earnings missed expectations by 2.27%.Factors to ConsiderThe Zacks Consensus Estimate for Iovance’s total revenues is pegged at around $2.9 million, while the same for earnings stands at a loss of 45 cents per share. Both metrics indicate improvements over the year-ago quarter’s levels.Iovance has two marketed products in its portfolio — Amtagvi (lifileuc ...

Iovance Biotherapeutics (NASDAQ: IOVA) stock price has rebounded sharply in the past few days as traders wait for the upcoming financial results. It rose by almost 6% on Friday and by over 3% on Monday. It has jumped to $14, almost 28% above its lowest point in April.Are you looking for signals & alerts from pro-traders? Sign-up to Invezz Signals™ for FREE. Takes 2 mins.Iovance earnings aheadCopy link to sectionIovance Biotherapeutics has been one of the best-performing companies on Wall Street as it soared ...

SAN CARLOS, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, will report its first quarter 2024 financial results on Thursday, May 9, 2024. Management will host a conference call and live audio webcast to discuss these results and provide a corporate update at 4:30 p.m. ET. To listen to the live or archived aud ...

SAN CARLOS, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, will report its first quarter 2024 financial results on Thursday, May 9, 2024. Management will host a conference call and live audio webcast to discuss these results and provide a corporate update at 4:30 p.m. ET. To listen to the live or archived au ...

SAN CARLOS, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that senior leadership plans to present at the following conferences: Chardan Annual Genetic Medicines & Cell Therapy Manufacturing Summit Fireside Chat: April 30, 2024 at 2:30 p.m. ETVirtual The Citizens JMP Life Sciences Conferenc ...